HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: Therapeutic implications for huntington's disease and alzheimer's disease

Antioxidants and Redox Signaling

Volumn 12, Issue 4, 2010, Pages 435-443

  Niatsetskaya, Zoya ^a,b   Basso, Manuela ^a,b   Speer, Rachel E ^a,b   McConoughey, Stephen J ^a,b   Coppola, Giovanni ^c   Ma, Thong C ^a,b   Ratan, Rajiv R ^a,b  

^a Burke Cornell Medical Research Institute   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROPROPIONIC ACID; DEFEROXAMINE; ENZYME INHIBITOR; HUNTINGTIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE INHIBITOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; SMALL INTERFERING RNA; SUCCINATE DEHYDROGENASE; TOXIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BRAIN CELL; CELL DEATH; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE FREQUENCY; HUNTINGTON CHOREA; MITOCHONDRION; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION INITIATION;

ALZHEIMER DISEASE; ANIMALS; CELL DEATH; ENZYME INHIBITORS; HUNTINGTON DISEASE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MITOCHONDRIA; NEURONS; NEUROPROTECTIVE AGENTS; NITRO COMPOUNDS; OXIDATIVE STRESS; PROCOLLAGEN-PROLINE DIOXYGENASE; PROPIONIC ACIDS; RATS; RNA, MESSENGER;

EID: 75149154666     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2800     Document Type: Article

References (38)

1. Aminova LR, Chavez JC, Lee J, Ryu H, Kung A, Lamanna JC, and Ratan RR. Prosurvival and prodeath effects of hypoxia-inducible factor-1alpha stabilization in a murine hippocampal cell line. J Biol Chem 280: 3996-4003, 2005.
2. Aminova LR, Siddiq A, and Ratan RR. Antioxidants, HIF prolyl hydroxylase inhibitors or short interfering RNAs to BNIP3 or PUMA, can prevent prodeath effects of the tran-scriptional activator, HIF-1alpha, in a mouse hippocampal neuronal line. Antioxid Redox Signal 10: 1989-1998, 2008.
3. Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Fer-rante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, and Beal MF. Creatine increase survival and delays motor symptoms in a trans-genic animal model of Huntington's disease. Neurobiol Dis 8: 479-491, 2001.
4. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, and Hyman BT. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13: 4181-4192, 1993.
5. Brouillet E, Jacquard C, Bizat N, and Blum D. 3-Nitropropionic acid: A mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 95: 1521-1540, 2005.
6. Browne SE. Mitochondria and Huntington's disease patho-genesis: Insight from genetic and chemical models. Ann NY Acad Sci 1147: 358-382, 2008.
7. Cha JH. Transcriptional signatures in Huntington's disease. Prog Neurobiol 83: 228-248, 2007.
8. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, and Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127: 59-69, 2006.
9. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, and Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54, 2001.
10. Gil JM and Rego AC. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 27: 2803-2820, 2008.
11. Hu CJ, Wang LY, Chodosh LA, Keith B, and Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23: 9361-9374, 2003.
12. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, and Kaelin WG, Jr. HIFalpha targeted for VHL-mediated destruction by proline hydrox-ylation: Implications for O2 sensing. Science 292: 464-468, 2001.
13. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gas-kell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, and Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
14. Kim JW, Tchernyshyov I, Semenza GL, and Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177-185, 2006.
15. Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M, Augood SJ, Faull RL, Olson JM, Bates GP, Jones L, and Luthi-Carter R. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 16: 1845-1861, 2007.
16. Lee JM, Ivanova EV, Seong IS, Cashorali T, Kohane I, Gu-sella JF, and MacDonald ME. Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet 3: e135, 2007.
17. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY, Mootha VK, Jager S, Vianna CR, Reznick RM, Cui L, Manieri M, Donovan MX, Wu Z, Cooper MP, Fan MC, Rohas LM, Zavacki AM, Cinti S, Shulman GI, Lowell BB, Krainc D, and Spiegelman BM. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119: 121-135, 2004.
18. Majamaa K, Gunzler V, Hanauske-Abel HM, Myllyla R, and Kivirikko KI. Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. J Biol Chem 261: 7819-7823, 1986.
19. Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, and Beal MF. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 18: 156-163, 1998.
20. Milakovic T and Johnson GV. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 280: 30773-30782, 2005.
21. Munujos P, Coll-Canti J, Gonzalez-Sastre F, and Gella FJ. Assay of succinate dehydrogenase activity by a colorimetric-continuous method using iodonitrotetrazolium chloride as electron acceptor. Anal Biochem 212: 506-509, 1993.
22. Murphy TH, Schnaar RL, and Coyle JT. Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J 4: 1624-1633, 1990.
23. Nardinocchi L, Puca R, Guidolin D, Belloni AS, Bossi G, Michiels C, Sacchi A, Onisto M, and D'Orazi G. Transcrip-tional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. Biochim Biophys Acta 1793: 368-377, 2009.
24. Nardinocchi L, Puca R, Sacchi A, and D'Orazi G. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer 8: 1, 2009.
25. Nguyen T, Hamby A, and Massa SM. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102: 11840-11845, 2005.
26. Ratan RR, Siddiq A, Aminova L, Langley B, McConoughey S, Karpisheva K, Lee HH, Carmichael T, Kornblum H, Coppola G, Geschwind DH, Hoke A, Smirnova N, Rink C, Roy S, Sen C, Beattie MS, Hart RP, Grumet M, Sun D, Freeman RS, Semenza GL, and Gazaryan I. Small molecule activation of adaptive gene expression: Tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injury. Ann NY Acad Sci 1147: 383-394, 2008.
27. Ratcliffe PJ. HIF-1 and HIF-2: Working alone or together in hypoxia? J Clin Invest 117: 862-865, 2007.
28. Ruan Q, Lesort M, MacDonald ME, and Johnson GV. Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum Mol Genet 13: 669-681, 2004.
29. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, and Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7: 77-85, 2005.
30. Semenza GL. Oxygen-dependent regulation of mitochon-drial respiration by hypoxia-inducible factor 1. Biochem J 405: 1-9, 2007.
31. Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, Patton SM, Connor JR, Cherny RA, Volitakis I, Bush AI, Langsetmo I, Seeley T, Gunzler V, and Ratan RR. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 280: 41732-41743, 2005.
32. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, and Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coac-tivators. Cell 127: 397-408, 2006.
33. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, Cattaneo E, and MacDonald ME. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 9: 2799-2809, 2000.
34. Wanner RM, Spielmann P, Stroka DM, Camenisch G, Ca-menisch I, Scheid A, Houck DR, Bauer C, Gassmann M, and Wenger RH. Epolones induce erythropoietin expression via hypoxia-inducible factor-1 alpha activation. Blood 96: 1558-1565, 2000.
35. Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, Beyer RP, Easley CN, Smith AC, Krainc D, Lu-quet S, Sweet IR, Schwartz MW, and La Spada AR. Ther-moregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 4: 349-362, 2006.
36. Willam C, Maxwell PH, Nichols L, Lygate C, Tian YM, Bernhardt W, Wiesener M, Ratcliffe PJ, Eckardt KU, and Pugh CW. HIF prolyl hydroxylases in the rat; Organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol 41: 68-77, 2006.
37. Yang YT, Ju TC, and Yang DI. Induction of hypoxia in-ducible factor-1 attenuates metabolic insults induced by 3-nitropropionic acid in rat C6 glioma cells. J Neurochem 93: 513-525, 2005.
38. Zaman K, Ryu H, Hall D, O'Donovan K, Lin KI, Miller MP, Marquis JC, Baraban JM, Semenza GL, and Ratan RR. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci 19: 9821-9830, 1999.